AU2019368247B2 - Antiviral prodrugs and nanoformulations thereof - Google Patents
Antiviral prodrugs and nanoformulations thereof Download PDFInfo
- Publication number
- AU2019368247B2 AU2019368247B2 AU2019368247A AU2019368247A AU2019368247B2 AU 2019368247 B2 AU2019368247 B2 AU 2019368247B2 AU 2019368247 A AU2019368247 A AU 2019368247A AU 2019368247 A AU2019368247 A AU 2019368247A AU 2019368247 B2 AU2019368247 B2 AU 2019368247B2
- Authority
- AU
- Australia
- Prior art keywords
- drug
- cab
- hiv
- prodrug
- nm2cab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024213169A AU2024213169B2 (en) | 2018-10-22 | 2024-08-22 | Antiviral prodrugs and nanoformulations thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748798P | 2018-10-22 | 2018-10-22 | |
| US62/748,798 | 2018-10-22 | ||
| PCT/US2019/057406 WO2020086555A1 (en) | 2018-10-22 | 2019-10-22 | Antiviral prodrugs and nanoformulations thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024213169A Division AU2024213169B2 (en) | 2018-10-22 | 2024-08-22 | Antiviral prodrugs and nanoformulations thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019368247A1 AU2019368247A1 (en) | 2021-06-03 |
| AU2019368247B2 true AU2019368247B2 (en) | 2025-02-27 |
Family
ID=70331730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019368247A Active AU2019368247B2 (en) | 2018-10-22 | 2019-10-22 | Antiviral prodrugs and nanoformulations thereof |
| AU2024213169A Active AU2024213169B2 (en) | 2018-10-22 | 2024-08-22 | Antiviral prodrugs and nanoformulations thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024213169A Active AU2024213169B2 (en) | 2018-10-22 | 2024-08-22 | Antiviral prodrugs and nanoformulations thereof |
Country Status (18)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4751717A3 (en) | 2018-10-22 | 2026-08-05 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN118873676A (zh) | 2018-11-29 | 2024-11-01 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| KR20240151256A (ko) | 2019-03-22 | 2024-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN116390924B (zh) | 2020-09-30 | 2025-11-07 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| CR20260070A (es) | 2021-01-19 | 2026-04-24 | Gilead Sciences Inc | COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315) |
| WO2023183472A1 (en) * | 2022-03-23 | 2023-09-28 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and use thereof |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| CN120936599A (zh) * | 2023-01-18 | 2025-11-11 | 歌礼生物科技(杭州)有限公司 | 整合酶抑制剂及其应用 |
| CN121194783A (zh) * | 2023-03-17 | 2025-12-23 | 依沙维治疗公司 | 抗病毒前药的制剂 |
| WO2024196661A1 (en) * | 2023-03-17 | 2024-09-26 | Exavir Therapeutics, Inc. | Crystalline forms of an antiviral prodrug |
| WO2024227037A1 (en) * | 2023-04-26 | 2024-10-31 | University Of Washington | Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods |
| WO2025011661A1 (zh) * | 2023-07-12 | 2025-01-16 | 歌礼生物科技(杭州)有限公司 | 整合酶抑制类的制剂及其制备方法 |
| TW202543636A (zh) | 2023-12-12 | 2025-11-16 | 美商 Viiv 醫療保健公司 | 結晶形式 |
| WO2025128498A1 (en) * | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| WO2026012272A1 (en) * | 2024-07-12 | 2026-01-15 | Ascletis Bioscience Co., Ltd. | Integrase inhibitor and use thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010011814A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2012061480A2 (en) * | 2010-11-02 | 2012-05-10 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| US20130171214A1 (en) * | 2010-09-16 | 2013-07-04 | Viiv Healthcare Company | Pharmaceutical Compositions |
| US20140011995A1 (en) * | 2010-08-05 | 2014-01-09 | Yukihito Sumino | Process for Preparing Compound Having HIV Integrase Inhibitory Activity |
| US20140221378A1 (en) * | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| US20150050241A1 (en) * | 2012-09-21 | 2015-02-19 | Epiphany Biosciences | Method of treating viral infections |
| US20150232479A1 (en) * | 2005-04-28 | 2015-08-20 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| US9216996B2 (en) * | 2012-12-21 | 2015-12-22 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
| US9758515B2 (en) * | 2010-09-24 | 2017-09-12 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| US20170326103A1 (en) * | 2014-08-12 | 2017-11-16 | Monash University | Lymph directing prodrugs |
| WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| EA201690146A1 (ru) | 2013-08-14 | 2016-07-29 | Ратиофарм Гмбх | Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира |
| US10081647B2 (en) * | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| EP3334722A1 (en) * | 2015-08-12 | 2018-06-20 | VIIV Healthcare UK (No.5) Limited | 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| LT3347352T (lt) * | 2016-08-19 | 2019-08-12 | Gilead Sciences, Inc. | Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| EP4751717A3 (en) | 2018-10-22 | 2026-08-05 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN118873676A (zh) | 2018-11-29 | 2024-11-01 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| MX2023005447A (es) | 2020-11-10 | 2023-09-25 | Unity Biotechnology Inc | Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos. |
-
2019
- 2019-10-22 EP EP26157385.1A patent/EP4751717A3/en active Pending
- 2019-10-22 CA CA3117453A patent/CA3117453A1/en active Pending
- 2019-10-22 CA CA3316153A patent/CA3316153A1/en active Pending
- 2019-10-22 AU AU2019368247A patent/AU2019368247B2/en active Active
- 2019-10-22 CN CN202310352412.0A patent/CN116375735B/zh active Active
- 2019-10-22 IL IL282551A patent/IL282551B2/en unknown
- 2019-10-22 CN CN201980085100.XA patent/CN113226319B/zh active Active
- 2019-10-22 KR KR1020247026674A patent/KR102908976B1/ko active Active
- 2019-10-22 JP JP2021523014A patent/JP7437051B2/ja active Active
- 2019-10-22 MX MX2021004679A patent/MX2021004679A/es unknown
- 2019-10-22 EP EP23160610.4A patent/EP4234561B1/en active Active
- 2019-10-22 ES ES19877349T patent/ES2970251T3/es active Active
- 2019-10-22 ES ES23160610T patent/ES3062664T3/es active Active
- 2019-10-22 KR KR1020217015211A patent/KR102856407B1/ko active Active
- 2019-10-22 EP EP19877349.1A patent/EP3870174B1/en active Active
- 2019-10-22 WO PCT/US2019/057406 patent/WO2020086555A1/en not_active Ceased
- 2019-10-22 EA EA202190974A patent/EA202190974A1/ru unknown
- 2019-10-22 SG SG11202104117WA patent/SG11202104117WA/en unknown
- 2019-10-22 MY MYPI2021002213A patent/MY207622A/en unknown
- 2019-10-22 IL IL320867A patent/IL320867A/en unknown
- 2019-10-22 EP EP23160303.6A patent/EP4234560A3/en not_active Withdrawn
- 2019-10-22 BR BR112021007622-0A patent/BR112021007622A2/pt unknown
-
2021
- 2021-03-22 US US17/301,030 patent/US11154557B2/en active Active
- 2021-04-22 PH PH12021550905A patent/PH12021550905A1/en unknown
- 2021-04-22 SA SA521421845A patent/SA521421845B1/ar unknown
- 2021-04-22 MX MX2023012166A patent/MX2023012166A/es unknown
- 2021-04-28 ZA ZA2021/02846A patent/ZA202102846B/en unknown
- 2021-05-24 US US17/303,228 patent/US11166957B2/en active Active
- 2021-05-24 US US17/303,229 patent/US11311547B2/en active Active
-
2022
- 2022-03-18 US US17/655,483 patent/US12168013B2/en active Active
-
2024
- 2024-04-22 ZA ZA2024/03101A patent/ZA202403101B/en unknown
- 2024-08-22 AU AU2024213169A patent/AU2024213169B2/en active Active
- 2024-12-09 US US18/973,233 patent/US20250099477A1/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150232479A1 (en) * | 2005-04-28 | 2015-08-20 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| WO2010011814A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| US20140011995A1 (en) * | 2010-08-05 | 2014-01-09 | Yukihito Sumino | Process for Preparing Compound Having HIV Integrase Inhibitory Activity |
| US20130171214A1 (en) * | 2010-09-16 | 2013-07-04 | Viiv Healthcare Company | Pharmaceutical Compositions |
| US9758515B2 (en) * | 2010-09-24 | 2017-09-12 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| WO2012061480A2 (en) * | 2010-11-02 | 2012-05-10 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| US20150050241A1 (en) * | 2012-09-21 | 2015-02-19 | Epiphany Biosciences | Method of treating viral infections |
| US9216996B2 (en) * | 2012-12-21 | 2015-12-22 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
| US20140221378A1 (en) * | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| US20170326103A1 (en) * | 2014-08-12 | 2017-11-16 | Monash University | Lymph directing prodrugs |
| WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12168013B2 (en) | Antiviral prodrugs and nanoformulations thereof | |
| US12257306B2 (en) | Antiviral prodrugs and nanoformulations thereof | |
| US11839623B2 (en) | Antiviral prodrugs and formulations thereof | |
| TW202308656A (zh) | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 | |
| US20210113558A1 (en) | Antiviral prodrugs and formulations thereof | |
| HK40093209A (en) | Antiviral prodrugs and nanoformulations thereof | |
| HK40092662A (en) | Antiviral prodrugs and nanoformulations thereof | |
| HK40052413A (en) | Antiviral prodrugs and nanoformulations thereof | |
| HK40052413B (en) | Antiviral prodrugs and nanoformulations thereof | |
| EA046194B1 (ru) | Противовирусные пролекарства и их наносоставы | |
| BR122024017400A2 (pt) | Compostos antivirais, nanopartícula, composição farmacêutica e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |